Psilocybin for hospitalized treatment-resistant depression
Treatments studied
Part of Mental health clinical trials.
This trial tests whether a single dose of psilocybin can help hospitalized patients with tough-to-treat depression. It focuses on people who haven't improved with standard antidepressants and need a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have moderate to severe depression that hasn't gotten better after trying at least two different antidepressants.
- You have a partner who lives with you and is willing to take part in the study.
- You do not have certain other mental health conditions like bipolar disorder, psychosis, or PTSD.
- You are medically stable (heart health, blood tests, etc.) and not pregnant if you are a woman.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a psilocybin-based treatment can help people with depression that has not improved after trying several antidepressants. You will receive the study treatment and have brain scans to see how it affects brain connections.
This trial tests whether taking very small, repeated doses of psilocybin (a substance found in magic mushrooms) along with talk therapy can help people with depression that hasn't gotten better with other treatments. You'll need to stop your current depression medications and avoid drugs or alcohol for the study period.
This trial tests whether psilocybin-assisted psychotherapy can help veterans and first responders with treatment-resistant depression and a co-occurring substance use disorder. It aims to see if this approach reduces depression and substance use.
This study tests whether trained monitors improve the safety and outcomes of psilocybin therapy for people with depression that hasn't responded to other treatments. Participants will receive psilocybin in a supervised setting and will need to temporarily stop other psychiatric medications.
This study tests whether a combination of psilocybin (a psychedelic substance) and transcranial magnetic stimulation (rTMS, a noninvasive brain stimulation) can help people with treatment-resistant depression. It involves daily visits to the research center for about 2 weeks.
This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.
Hear when a new Treatment Resistant Depression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.